The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AL | Neonatal fragment crystallizable receptor (FcRn) inhibitors | |
5
|
L04AL03 |
| Active Ingredient |
|---|
|
Nipocalimab is a human IgG1 monoclonal antibody specifically targeting the IgG Fc binding site of FcRn with high specificity and high affinity at both neutral (extracellular) and acidic pH (intracellular) resulting in the reduction of circulating IgG, including IgG autoantibodies, without affecting other immunoglobulins (IgA, IgE or IgM). |
| Document | Type | Information Source | |
|---|---|---|---|
| IMAAVY Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| IMAAVY Concentrate for solution for injection | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.